$23.84
2.49%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
IE000GID8VI0
Symbol
GHRS

GH Research PLC Stock price

$23.84
-5.08 17.57% 1M
+10.19 74.65% 6M
+11.14 87.72% YTD
+10.44 77.91% 1Y
+14.04 143.27% 3Y
+3.69 18.31% 5Y
+4.59 23.84% 10Y
+4.59 23.84% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-0.61 2.49%
ISIN
IE000GID8VI0
Symbol
GHRS
Industry

Is GH Research PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.4b
Net debt
positive
Cash
$267.3m
Shares outstanding
62.1m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
6.2
Financial Health
Equity Ratio
97.0%
Return on Equity
-17.3%
ROCE
-25.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-66.4m
EBIT
$-66.7m
Net Income
$-56.4m
Free Cash Flow
$-45.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-29.6%
EBIT
-29.5%
Net Income
-34.0%
Free Cash Flow
10.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-0.7
Short interest
10.0%
Employees
73
Rev per Employee
$0.0

GH Research PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a GH Research PLC forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a GH Research PLC forecast:

Buy
94%
Hold
6%

Financial data from GH Research PLC

Mar '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
36% 36%
-
- Research and Development Expense 43 43
27% 27%
-
-66 -66
30% 30%
-
- Depreciation and Amortization 0.35 0.35
13% 13%
-
EBIT (Operating Income) EBIT -67 -67
30% 30%
-
Net Profit -56 -56
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about GH Research PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GH Research PLC Stock News

Neutral
GlobeNewsWire
●
about 2 months ago
Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials  Further strengthening of US and EU mebufotenin patent estate Phase 2a results in postpartum depression published in The Journal of Clinical Psychiatry Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026 DUBLIN, Aug. 06, 2026 (GLOBE NEWSWI...
Positive
Proactive Investors
●
2 months ago
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sc...
Neutral
GlobeNewsWire
●
4 months ago
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled “Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depress...
More GH Research PLC News

Company Profile

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Dr. Valcheva
Employees 73
Founded 2021
Website www.ghres.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today